权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

RC-BMAC

基本信息

批准号：
10447585
负责人：
TOREN FINKEL
金额：
$ 12.65万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
2004
资助国家：
美国
起止时间：
2004-09-30 至 2025-06-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10447585
关键词：
Adoption Aging American Animal Model Animals Area Back Basic Science Biological Biological Markers Biological Models Biological Process Biological Products Biological Sciences Biology Biology of Aging CRISPR screen Capsicum Chemicals Clinical Clinical Trials Clustered Regularly Interspaced Short Palindromic Repeats Collaborations Complement Consultations Core Facility Development Doctor of Philosophy Drosophila genus Elderly Equilibrium Faculty Fostering Foundations Funding Future Gait Genes Genetic Geriatrics Geroscience Goals Human Impairment Individual Inflammation Institutes International Intervention Investments Knowledge Laboratories Language Leadership Link Medical Methodology Mission Molecular Molecular Target Muscle function Muscle satellite cell Neurosciences Organism Pharmacology Phenotype Pilot Projects Pre-Clinical Model Process Reagent Research Personnel Research Support Research Training Resources Rodent Science Scientist System Techniques Technology Translating Translations Visit Work Zebrafish age related base biomarker development clinical care clinical practice design exosome first-in-human gene therapy healthspan high throughput analysis high throughput screening improved innovation insight instrumentation member metabolomics microbiome molecular drug target molecular targeted therapies muscle physiology novel novel marker novel therapeutics pre-clinical preservation prevent recruit screening single-cell RNA sequencing small molecule libraries square foot targeted treatment tool translational study trend whole genome

项目摘要

BMAC Summary/Abstract: The impact of basic science is increasingly influencing medical practice. This trend will likely only accelerate in the near future, as techniques including gene therapy and CRISPR-based gene editing begin to impact clinical care. The continued progress of this approach, and its application to geriatrics, requires a seamless integration of basic, translational and clinical researchers. In order to facilitate this integration, we are proposing creation of a new Core for this application. Entitled, the Biology of Mobility and Aging Core (BMAC), this Core will foster the work of clinicians and basic scientists by linking the tenets of `geroscience' to advance new treatments to improve balance and mobility. These include the identification of new biomarkers, elucidating new molecular targets for drug therapy, using in-depth animal phenotyping to assess new biologic agents, and generally promoting back and forth translation between human and basic studies. This work will ultimately help catalyze the ability of our Pepper Center to conduct first-in-human clinical trials of novel agents to preserve mobility and balance in late life. Excitingly, some of these efforts have already been initiated. By supporting pilot, developmental, and external projects, the BMAC also enhances the rigor, strength and quality of our OAIC. Moreover, BMAC resources that include state-of-the-art instrumentation and methodologies, a range of seminars and didactics, as well as laboratory visits, unique genetic reagents and in-depth consultations, will become widely and easily accessible to Pepper investigators. The BMAC includes internationally renowned faculty members who constitute a group of senior investigators with knowledge spanning neuroscience, muscle physiology, pre-clinical animal phenotyping, metabolomics, translational pharmacology, the microbiome and high throughput genetic and chemical screening platforms. All BMAC faculty operate state-of-the-art and well- funded laboratories in areas relevant to the biology of mobility and aging.

BMAC总结/文摘: